Clinical Trials Logo

Anemia clinical trials

View clinical trials related to Anemia.

Filter by:

NCT ID: NCT00211055 Completed - Anemia Clinical Trials

A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children

Start date: September 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine the incidence of anemia and blood transfusions and management of these in critically ill children

NCT ID: NCT00210977 Withdrawn - Anemia Clinical Trials

A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies

Start date: December 2005
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the presence of anti erythropoietin antibodies (anti EPO Ab) in participants responding to any erythropoietin receptor agonist (ERA) therapy to treat or prevent anemia without loss of effectiveness to see if they will develop pure red cell aplasia or loss of effectiveness to recombinant erythropoietin and to measure the duration of effectiveness of ERA therapy.

NCT ID: NCT00210834 Completed - Anemia Clinical Trials

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare end of study hemoglobin levels between Epoetin alfa at 40,000 units administered subcutaneously once every week and at 80,000 units subcutaneously every two weeks in anemic patients with cancer receiving chemotherapy. The secondary objectives of the study are to assess the Hb response, time to Hb response, transfusion requirements, and safety.

NCT ID: NCT00210795 Terminated - Anemia Clinical Trials

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess changes in physical function in elderly patients (>= 65 years of age) with chronic anemia (Hb <= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo

NCT ID: NCT00210756 Completed - Anemia Clinical Trials

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the pharmacokinetics (PK) of six different dosing regimens of epoetin alfa (PROCRIT®) in anemic critically ill subjects

NCT ID: NCT00210743 Completed - Anemia Clinical Trials

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the hemoglobin response rate in subjects with anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRIT®) every 2 weeks

NCT ID: NCT00210730 Terminated - Anemia Clinical Trials

The Duration Study

Start date: June 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of epoetin alfa (PROCRIT®) administered subcutaneously (sc) once every week (qw) vs. no epoetin alfa (PROCRIT®) treatment in patients with cancer who are anemic.

NCT ID: NCT00210626 Terminated - Anemia Clinical Trials

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate the physical function outcomes in anemic, critically ill, trauma subjects treated with epoetin alfa (PROCRIT®) compared to placebo.

NCT ID: NCT00210600 Completed - Anemia Clinical Trials

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of PROCRIT (Epoetin alfa) when administered at 120,000 Units once every three weeks by comparing early dosing (Hb 11g/dL-12g/dL) vs. standard dosing (Hb< 11g/dL).

NCT ID: NCT00210587 Completed - Neoplasms Clinical Trials

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa (PROCRIT®) administered 80,000 Units every three weeks in cancer patients that are not receiving chemotherapy or radiation therapy.